Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Epigenetic Modifiers Take Center Stage, Big Pharma Takes Notice

Apr 16 2012

• By Malorye Allison

Related Content

HDAC Inhibitor Mysteries Remain As Candidates Advance

Dec 01 2011

Eisai Deal Puts Epizyme In Position To Advance Lead Program

Mar 10 2011

Genentech, Constellation Enter Largest Epigenetics Tie-Up Yet

Jan 17 2012

<em>Erivedge</em> May Be The <em>Gleevec</em> Of Hedgehog Inhibitors

Feb 13 2012

Deals Of The Week: Celgene/Acetylon, Cytomedix/Aldagen, Vernalis/Tris Pharma

Feb 13 2012

The HDAC Field Heats Up: An Interview with Syndax CEO Joanna Horobin

Feb 27 2012

Acetylon Pharmaceuticals Inc.

Oct 01 2011

Related Companies

GSK plc

Eisai Co., Ltd.

Abbott

Genentech, Inc.

Bristol Myers Squibb Company

Merck & Co., Inc.

Takeda Pharmaceutical Co. Ltd.

Novartis AG

4SC AG

Les Laboratoires Servier

GSK plc

MGI Pharma

Constellation Pharmaceuticals, Inc.

Curis, Inc.

Epizyme, Inc.

Syndax Pharmaceuticals, Inc.

Ventana Medical Systems, Inc.

Roche Holding AG

Additional Topics

Deals BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window